What is included in maintenance therapy for acute lymphoblastic leukemia (ALL)?

Updated: Oct 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Maintenance therapy consists of prednisone, vincristine (Oncovin), methotrexate, and mercaptopurine (Purinethol) (ie, POMP protocol). From 1992-2000, 288 patients received hyper-CVAD at MD Anderson Cancer Center; of those, 17% of patients had Philadelphia chromosome–positive (Ph+) ALL, and 13% had T-cell ALL. [28] Overall, 92% of patients obtained a CR. The 5-year survival and percentage of patients in CR at 5 years were both 38%. Patients with Ph+ ALL had a 92% CR rate but only a 12% 5-year survival. Patients with T-cell ALL had a 75% CR rate and a 48% 5-year survival. Patients with Burkitt ALL had a 93% CR rate and a 67% 5-year survival. [28]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!